about
Role of necroptosis in the pathogenesis of solid organ injuryDiscovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with NecroptosisNecroptosisOptimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorUsing Small Molecules to Dissect Non-apoptotic Programmed Cell Death: Necroptosis, Ferroptosis, and Pyroptosis.Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation.Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury.Necroptosis: an alternative cell death program defending against cancer.RIP3: a molecular switch for necrosis and inflammation.Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice.RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome.The role of necroptosis, an alternative form of cell death, in cancer therapy.Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death.Ars Moriendi; the art of dying well - new insights into the molecular pathways of necroptotic cell death.Structural basis of cell apoptosis and necrosis in TNFR signaling.A tale of two domains - a structural perspective of the pseudokinase, MLKL.Emerging Roles for RIPK1 and RIPK3 in Pathogen-Induced Cell Death and Host Immunity.Generation of small molecules to interfere with regulated necrosis.Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.Effects of silencing RIP1 with siRNA on the biological behavior of the LoVo human colon cancer cell lineComplex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis.Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.Necroptosis and Cancer.Necroptosis in cancer: An angel or a demon?Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.Loss of caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis.6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury.Positive and negative phosphorylation regulates RIP1- and RIP3-induced programmed necrosisSorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells.RIP3 induces apoptosis independent of pronecrotic kinase activity.Regulated necrosis in HeLa cells induced by ZnPc photodynamic treatment: a new nuclear morphology.Betanodavirus B2 protein triggers apoptosis and necroptosis in lung cancer cells that suppresses autophagy.A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.RIP1 kinase activity-dependent roles in embryonic development of Fadd-deficient mice.Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).
P2860
Q27023218-C398ACF1-B945-4452-8289-973244886C9FQ27684187-8F950DC6-CE1E-42BA-81A5-911F41D2ED14Q34039704-EF134BDB-45A7-4707-9089-316393A183A6Q35697350-9A5F1233-2B31-4973-BE8F-5F77FBBB3F44Q35781653-01B0DD5D-DA19-4F59-A19A-A0EE639DA985Q35828387-699574FE-E108-4A4C-8002-75268AE5C957Q35974144-C943B7B2-E675-42F0-A203-511C027E6623Q36084130-02E435BC-0F80-4F61-92DE-A8F39BE712A8Q36179559-14C79087-657F-41B6-A607-69370AB31975Q36880241-F618724D-F595-4AD4-BF22-5400B11F813FQ37098143-318DC106-7865-4813-BBE7-137794699E83Q37555484-BBBB2D5E-F183-4325-AA51-AB5F3B591B7BQ37642622-923E4E9A-4DB1-40DD-B8EA-54FCB95CE2A4Q38123208-3230458F-0D32-4A66-A2F4-A7257186388BQ38152946-6BA6A9A1-6893-4C32-851A-F630E009CD4AQ38182403-92560100-71EF-48C5-9A14-56F677185A89Q38275782-D501E4BF-2DB9-4BC4-A720-2A7D0B1312C6Q38580336-89ACE08D-E3E3-46A5-A5A5-511CBE26D70DQ38589407-7051A7F8-CFE5-4699-BC82-804546FEF35CQ38799144-32E4F18C-4494-45B6-899F-E63F59B3A63FQ38939282-F34B2667-E4D5-404E-A86C-AF70204BEE48Q38959073-ACB57E35-3498-482B-9C8B-0BE623C422EDQ38984420-70E0F5F7-A902-412F-9612-19C35D5BFBC6Q39105381-84687923-28DA-48A5-9E67-1345403AB07BQ39226865-04D1833A-1956-460F-8FA9-2F1B763549E7Q39268644-0CCA4A5D-1666-4F17-B368-D167CE99BA4CQ39398933-D3B73F29-9726-4034-A9DC-FA279D2A6CBFQ40132104-E0D076A0-5C5F-4270-BF04-F3186932C1EEQ40153668-FB629A53-CF10-4E72-82D9-D7A40A275A03Q41023161-821825A5-D12C-43B5-B30A-B31583520C46Q41919743-63907961-AE65-4DE4-BB02-0DCC4FF46DA8Q42153354-66B04B42-8B50-4323-A347-80CD1DA55396Q42366610-907E8AB6-2CF1-4CFB-A075-315CAB1786C5Q42379853-C9A4115F-F0C0-435A-BE88-F5B098D476C4Q43092056-C87F2FB5-CDD5-4CBF-AB10-73B605B5C74AQ46246683-8D807972-FB7B-4D66-B9C6-DFC9A6D608ABQ48215990-9EA60EA9-2BD2-4835-A46B-2DC663F13D11Q48336481-EC1693C9-E79F-4AD3-B9C8-C1E2B96DCC05Q48509895-54BF4872-31E6-490B-871A-12B8FD930AAFQ49025576-44478B4F-8044-4C25-86B6-BA18FC95FDF9
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Structural basis of RIP1 inhibition by necrostatins
@ast
Structural basis of RIP1 inhibition by necrostatins
@en
Structural basis of RIP1 inhibition by necrostatins
@en-gb
Structural basis of RIP1 inhibition by necrostatins
@nl
type
label
Structural basis of RIP1 inhibition by necrostatins
@ast
Structural basis of RIP1 inhibition by necrostatins
@en
Structural basis of RIP1 inhibition by necrostatins
@en-gb
Structural basis of RIP1 inhibition by necrostatins
@nl
prefLabel
Structural basis of RIP1 inhibition by necrostatins
@ast
Structural basis of RIP1 inhibition by necrostatins
@en
Structural basis of RIP1 inhibition by necrostatins
@en-gb
Structural basis of RIP1 inhibition by necrostatins
@nl
P2093
P3181
P1433
P1476
Structural basis of RIP1 inhibition by necrostatins
@en
P2093
Chuangye Yan
Jenny Maki
Junying Yuan
Yexing Liu
P3181
P356
10.1016/J.STR.2013.01.016
P407
P577
2013-03-05T00:00:00Z